Rockville, Md., January 24, 2011 In collaboration with key stakeholders, the United States Pharmacopeial Convention (USP) and the Indian Pharmacopoeia Commission (IPC) will host the 2011 IPC-USP 10th Science & Standards Symposium on February 17 and 18, 2011 in Hyderabad, India. The event reflects India's rise as a supplier of medicines worldwide, bringing USP closer to its Indian counterpart in the interest of promoting global public health.
The symposium aims to facilitate a science-based dialogue among key stakeholderssuch as standard-setting bodies, government officials, policy makers, pharmaceutical manufacturers and academiato address relevant topics affecting the region and thereby promote access to quality medicines. Attendees will have the opportunity to network with thought leaders, obtain industry benchmark information and contribute early in the standard-setting process for both IPC and USP.
Along with USP and IPC, additional co-sponsors include Bulk Drug Manufacturers Association (BDMA), Indian Drug Manufacturers' Association (IDMA), Organization of Pharmaceutical Producers of India (OPPI) and Pharmacy Council of India (PCI).
"For a decade, these annual IPC-USP meetings have brought together key experts and innovators throughout the Indian pharmaceutical landscape as well from the United States and other countries," said Roger L. Williams, M.D., chief executive officer, USP. "As India's role in the global pharmaceutical industry continues its rapid growth, collaborations within India and with partners around the world are essential to helping to ensure public health." Previous events were known as Annual Scientific Meetings.
Sessions on chemical drugs will be part of symposium highlights, covering topics as varied as quality by design, standards-setting, impurities, chemical reference materials/uncertainty measurement and strategies for combating counterfeit drugs. Biological drugs will also be emphasized in sessions that explore regulatory approaches; standards for biologics and biotechnology drugs; critical quality attributes; reference materials; standards for vaccines and monoclonal antibodies and strategies for combating adulteration of drugs.
"The IPC values its longstanding relationship with USP," stated G.N. Singh, Ph.D., secretary-cum-scientific director, IPC. "We are confident this year's forum will result in a better understanding among participants of the status and issues facing the IPC and USP in standards-setting."
|Contact: Theresa Laranang-Mutlu|